5 completed, 2 terminated. 3 Phase 3, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow inclacumab: new trials by email Literature Review of inclacumab trials Research Report on inclacumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers inclacumab - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 62 | 2013-06-01 | 2016-11-02 |
| A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention Percutaneous Coronary Intervention (PCI), RO4905417, placebo - Myocardial Infarction | Phase 2 | Completed | Hoffmann-La Roche | 532 | 2011-05-01 | 2016-11-02 |
| A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery Placebo, RO4905417 - Coronary Heart Disease, Graft Occlusion, Vascular | Phase 2 | Completed | Hoffmann-La Roche | 384 | 2010-12-01 | 2016-11-02 |
| A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD). RO4905417, placebo - Peripheral Arterial Disease (PAD) | Phase 1 | Completed | Hoffmann-La Roche | 72 | 2008-09-01 | 2016-11-02 |
Anemia, Sickle Cell (3) · Hematologic Diseases (3) · Vaso-Occlusive Crises (3) · Sickle Cell Trait (2) · Coronary Disease (1) · Myocardial Infarction (1) · Peripheral Arterial Disease (1)
Hoffmann-La Roche (4) · Pfizer (3)
United States (7) · Brazil (3) · Canada (3) · Colombia (3) · Kenya (3) · Lebanon (3) · Nigeria (3) · Oman (3) · Saudi Arabia (3) · Turkey (Türkiye) (3) · France (2) · Tanzania (2) · Australia (1) · Egypt (1) · Germany (1)